 text from a representative informed consent document | |
| other names | PARAMOUNT, NCT00789373 |
|---|---|
| sponsor | Eli Lilly and Company |
| number of participants | 939 |
| start | November 2008 |
| end | September 2013 |
| primary completion | June 2010 |
The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly and Company and was conducted in several European countries and Canada. It was registered in November 2008 and was projected to end in September 2013.
PARAMOUNT found that maintenance therapy with pemetrexed for patients with advanced non-squamous NSCLC was an effective and well-tolerated treatment option in those patients who had not had progress after initial therapy with pemetrexed plus cisplatin.